Press release
ANGPTL3 Therapy Market Rises with Focus on Cardiovascular Health by 2025-2033 | Regeneron Pharmaceuticals, Inc., Arrowhead Pharmaceuticals Inc., Amgen Inc., Silence Therapeutics, Eli Lilly, Novartis AG
ANGPTL3 Therapy Market
The latest ANGPTL3-Lowering Therapy Market Report by DataM Intelligence offers a clear analysis of global trends, market size, key players, and growth drivers. Covering emerging technologies, evolving care models, and regulatory insights, it provides strategic intelligence to help stakeholders navigate the dynamic healthcare landscape through 2025-2033
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access):
https://www.datamintelligence.com/download-sample/angptl3-lowering-therapy-market?ophp
ANGPTL3-lowering therapy targets angiopoietin-like 3 protein to reduce lipid levels and cardiovascular risk in patients with genetic dyslipidemia. The market is in early stages but gaining momentum with clinical trial success and growing interest in precision cardiometabolic therapies.
ANGPTL3-Lowering Therapy Market Competitors Overview:
Regeneron Pharmaceuticals, Inc., Arrowhead Pharmaceuticals Inc., Amgen Inc., Ionis Pharmaceuticals, Inc. (Akcea Therapeutics), Silence Therapeutics, Eli Lilly and Company, Novartis AG, Verve Therapeutics, Inc., and CRISPR Therapeutics, among others.
Important Industry Updates of 2024 and 2025:
✅ In May 2024, Arrowhead Pharmaceuticals recently presented new Phase 2 clinical data for Zodasiran (formerly known as ARO-ANG3), an investigational RNA interference (RNAi) therapy being developed for patients with mixed hyperlipidemia, a condition characterized by elevated levels of multiple types of blood lipids, such as cholesterol and triglycerides. Zodasiran works by targeting and reducing the production of angiopoietin-like protein 3 (ANGPTL3), a protein made in the liver that plays a key role in regulating lipid and lipoprotein metabolism.
ANGPTL3-Lowering Therapy Market Segments Overview:
∎ By Treatment Type (Monoclonal Antibodies, Antisense Oligonucleotides (ASOs), RNA Interference (RNAi) Therapies (siRNA), CRISPR-Based Gene Editing, Others)
∎ By Application (Familial Hypercholesterolemia (FH), Refractory Hyperlipidemia, Mixed Dyslipidemia, Cardiovascular Diseases, Others)
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/angptl3-lowering-therapy-market?ophp
Methodology and Scope:
This ANGPTL3-Lowering Therapy Market report is developed using a robust research methodology that combines primary interviews, insights from industry experts, and verified secondary sources such as company filings, trade journals, and trusted databases. It follows a bottom-up and top-down approach to ensure data accuracy through triangulation. The scope of the report covers current market trends, growth potential, and strategic developments across global and regional markets.
Regional Overview for ANGPTL3-Lowering Therapy Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Looking For Exclusive Full Report? Get it here: https://www.datamintelligence.com/buy-now-page?report=angptl3-lowering-therapy-market?ophp
The Report Includes:
➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Go-to-market Strategy.
➡ Neutral perspective on the market performance.
➡ Customized regional/country reports as per request and country level analysis.
➡ Potential & niche segments and regions exhibiting promising growth covered.
People Also Ask:
➤ What are the global sales, production, import, and export trends in the ANGPTL3-Lowering Therapy market?
➤ Who are the top manufacturers, and what are their output, pricing, and revenue figures?
➤ What key opportunities and challenges do vendors face in this market?
➤ Which product types, applications, or end-users are driving growth and holding market share?
➤ What are the main growth drivers and restraints affecting the ANGPTL3-Lowering Therapy market?
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ANGPTL3 Therapy Market Rises with Focus on Cardiovascular Health by 2025-2033 | Regeneron Pharmaceuticals, Inc., Arrowhead Pharmaceuticals Inc., Amgen Inc., Silence Therapeutics, Eli Lilly, Novartis AG here
News-ID: 4103066 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
United States Prime Editing and CRISPR Market 2025 | Growth Drivers, Key Players …
Market Size and Growth
Prime Editing and CRISPR Market is estimated to grow at a CAGR of 24.1% during the forecast period (2024-2031).
Key Development:
United States: Recent Industry Developments
✅ July 2025 - Prime Medicine announced an additional investment of up to $24 million from the Cystic Fibrosis Foundation to advance gene editing therapy targeting the G542X mutation, a prevalent cystic fibrosis-causing mutation with no current therapies.
✅ July 2025 - CRISPR…
United States Clinical Workflow Solutions Market 2025 | Growth Drivers, Market F …
Market Size and Growth
The Clinical Workflow Solutions Market size is growing at a high CAGR 12.3% during the forecast period (2023-2030).
Key Development:
United States: Recent Industry Developments
✅ In August 2025, Elation Health unveiled a significant AI expansion to its clinical-first platform, integrating native AI tools across all products at no additional cost. This enhancement aims to reduce administrative burdens and improve primary care workflows.
✅ In June 2025, Commure launched Commure Agents,…
United States Smart Robot Market 2025 | Growth Drivers, Market Forecast, Competi …
Market Size and Growth
The Global Smart Robot Market size is growing at a high CAGR during the forecast period (2024-2031).
Key Development:
United States: Recent Industry Developments
✅ In September 2025, ReWalk Robotics introduced an advanced lower-limb exoskeleton designed for stroke and spinal injury rehabilitation. This medical service robot aims to enhance mobility and independence for individuals with lower-limb disabilities, marking a significant advancement in healthcare robotics.
✅ In July 2025, Meta launched its…
United States Bio Active Protein Market 2025 | Growth Drivers, Market Forecast, …
Market Size and Growth
The Global "Bio Active Protein Market" is expected to grow at a CAGR during the forecast period 2024-2031
Key Development:
United States: Recent Industry Developments
✅ In September 2025, The Protein Brewery secured $35.6 million in Series B funding to scale its fungi-based bioactive protein production platform. The investment aims to accelerate the commercial launch of its sustainable protein ingredients in the U.S. and Singapore markets.
✅ In September 2025, Glanbia,…
More Releases for ANGPTL3
Hypertriglyceridemia Market is expected to reach USD 39 billion by 2034
Hypertriglyceridemia is a common lipid disorder characterized by elevated levels of triglycerides in the blood, often associated with obesity, diabetes, metabolic syndrome, and genetic predisposition. While mild to moderate hypertriglyceridemia is widespread, severe cases can lead to acute pancreatitis, cardiovascular disease, and liver complications. The condition is both a standalone metabolic issue and a risk factor for a broader spectrum of chronic diseases.
Download Full PDF Sample Copy of Market Report…
Global ANGPTL3-lowering Therapy Market (2025-2033): 30.9% CAGR Fueled by RNAi & …
The global ANGPTL3-lowering therapy market was valued at US$ 99.75 million in 2024 and is projected to reach US$ 1,096.42 million by 2033, growing at a compound annual growth rate (CAGR) of 30.9% during the forecast period 2025-2033.
Market Overview
ANGPTL3-lowering therapies target angiopoietin-like protein 3 (ANGPTL3), a liver-produced protein that regulates lipid metabolism. These therapies, including monoclonal antibodies, antisense oligonucleotides (ASOs), and RNA interference (RNAi) treatments, reduce low-density lipoprotein cholesterol (LDL-C)…
Homozygous Familial Hypercholesterolemia (HoFH) Market Massive Growth opportunit …
Introduction
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic lipid disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels from birth, often exceeding 500 mg/dL. Caused by mutations in both alleles of the LDLR, APOB, or PCSK9 genes, HoFH leads to early-onset atherosclerosis, cardiovascular disease, and premature mortality if untreated.
Historically, management relied on lipid-lowering agents, LDL apheresis, and lifestyle modifications. However, the last decade has witnessed a paradigm shift with…
Homozygous Familial Hypercholesterolemia Market 2025 | Market Growth, Genetic Sc …
Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2030 growing with a CAGR of 2.5% during the forecast period 2023-2030, according to DataM Intelligence research report, as per DataM intelligence research report.
Homozygous Familial Hypercholesterolemia Market: Recent Industry Developments
United States
✅ Regeneron announced the FDA extension of Evkeeza use to children aged 5-11 with HoFH, making it the first ANGPTL3 inhibitor…
Homozygous Familial Hypercholesterolemia Pipeline Insight 2025: RNA-Based Therap …
DelveInsight's "Homozygous Familial Hypercholesterolemia (HoFH) - Pipeline Insight, 2025" offers a deep analysis of the evolving therapeutic landscape for one of the most severe and genetically driven lipid disorders. HoFH, affecting ~1 in 300K individuals worldwide, is characterized by markedly elevated LDL-C levels from birth and rapid progression to premature atherosclerotic cardiovascular disease. Despite statins, ezetimibe, and PCSK9 inhibitors, most HoFH patients remain undertreated due to minimal or absent LDL…
ANGPTL3 Inhibitor Market Poised for Significant Growth with Emerging Therapies, …
(Albany, USA) DelveInsight's ANGPTL3 Inhibitor Market Insights report provides an in-depth analysis of treatment practices, emerging ANGPTL3 inhibitors, market share of individual therapies, and the current and forecasted ANGPTL3 inhibitor market size from 2021 to 2034 across the 7MM [the United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
The ANGPTL3 inhibitor market is expected to witness substantial growth in the coming years, driven by increasing…
